A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

por Schöffski, Patrick, Cresta, Sara, Mayer, Ingrid A., Wildiers, Hans, Damian, Silvia, Gendreau, Steven, Rooney, Isabelle, Morrissey, Kari M., Spoerke, Jill M., Ng, Vivian W., Singel, Stina M., Winer, Eric
Publicado 2018

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

por Fiedler, Walter, Cresta, Sara, Schulze-Bergkamen, Henning, De Dosso, Sara, Weidmann, Jens, Tessari, Anna, Baumeister, Hans, Danielczyk, Antje, Dietrich, Bruno, Goletz, Steffen, Zurlo, Alfredo, Salzberg, Marc, Sessa, Cristiana, Gianni, Luca
Publicado 2018

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

por Lorusso, Domenica, Maltese, Giuseppa, Sabatucci, Ilaria, Cresta, Sara, Matteo, Cristina, Ceruti, Tommaso, D’Incalci, Maurizio, Zucchetti, Massimo, Raspagliesi, Francesco, Sonetto, Cristina, Sinno, Valentina, Ronzulli, Dominique, Giolitto, Serena, de Braud, Filippo
Publicado 2020

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclon...

por Cona, Maria Silvia, Lecchi, Mara, Cresta, Sara, Damian, Silvia, Del Vecchio, Michele, Necchi, Andrea, Poggi, Marta Maria, Raggi, Daniele, Randon, Giovanni, Ratta, Raffaele, Signorelli, Diego, Vernieri, Claudio, de Braud, Filippo, Verderio, Paolo, Di Nicola, Massimo
Publicado 2019

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

por Jhaveri, Komal, Juric, Dejan, Yap, Yoon-Sim, Cresta, Sara, Layman, Rachel M., Duhoux, Francois P., Terret, Catherine, Takahashi, Shunji, Huober, Jens, Kundamal, Nicole, Sheng, Qing, Balbin, Alejandro, Ji, Yan, He, Wei, Crystal, Adam, De Vita, Serena, Curigliano, Giuseppe
Publicado 2021

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

por de Braud, Filippo, Machiels, Jean-Pascal H., Boggiani, Daniela, Rottey, Sylvie W.H., Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Damian, Silvia, Lapeire, Lore D.F., Tiseo, Marcello, Dermine, Alexandre, Ould-Kaci, Mahmoud, Braunger, Juergen, Rascher, Juliane, Fischer, Daniela, Hoefler, Josef, Mariani, Gabriella L., Cresta, Sara
Publicado 2020